Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Mary Pinder"'
Publikováno v:
International Journal of Nephrology, Vol 2011 (2011)
This paper addresses the epidemiology of AKI specifically in relation to recent changes in AKI classification and revisits the controversies regarding the timing of initiation of dialysis and the use of peritoneal dialysis as a renal replacement ther
Externí odkaz:
https://doaj.org/article/b8afa55cee284d93894e7da1314db064
Publikováno v:
Critical Care and Resuscitation.
Autor:
Alison Marguerite Ivey, Mary Pinder-Schenck, Frederic J. Kaye, Andres Gordillo Villegas, Maria Zajac-Kaye, Alberto Chiappori, Wei Hou, Chunxia Cao, Priya K. Gopalan
Publikováno v:
Oncotarget
Aberrant activation of CDK4/6 kinase is the most common somatic event in non-small cell lung cancer (NSCLC). Palbociclib is a highly specific CDK4/6 inhibitor shown to inhibit cell cycle progression and promote cellular senescence. We conducted a pha
Autor:
Tawee Tanvetyanon, Melanie Mediavilla-Varela, Renee Smilee, David Noyes, Rebecca Devane, Scott J. Antonia, Mary Pinder-Schenck, Emily L. Hopewell, Theresa A. Boyle, Charles Williams, Jhanelle E. Gray, Alberto Chiappori, Ben C. Creelan, Soner Altiok, Jongphil Kim, Linda Kelley, Farah Khalil, Eric B. Haura
Publikováno v:
Cancer Immunology, Immunotherapy
The GM.CD40L vaccine, which recruits and activates dendritic cells, migrates to lymph nodes, activating T cells and leading to systemic tumor cell killing. When combined with the CCL21 chemokine, which recruits T cells and enhances T-cell responses,
Publikováno v:
Journal of Pharmacy Practice and Research. 51:88-89
Autor:
Scott G. Soltys, Joel W. Neal, Clara Y.H. Choi, Hsiang Hsuan Michael Yu, Leslie A. Modlin, John R. Adler, Steven D. Chang, Heather A. Wakelee, Griffith R. Harsh, Mary Pinder-Schenck
Publikováno v:
International journal of radiation oncology, biology, physics, vol 99, iss 1
PurposeTo determine the maximum tolerated dose (MTD) of vorinostat, a histone deacetylase inhibitor, given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLC) brain metastases. Secondary objectives were to de
Autor:
Donald A. Richards, Wu Chou Su, Scott P. Myrand, Jin Hyoung Kang, Richard K. Rosenberg, Ji Lin, Sameera R. Wijayawardana, Mary Pinder-Schenck, Scott M. Hynes, Giorgio V. Scagliotti, Aimee Bence Lin, Emily Nash Smyth, David J. Smith, Keunchil Park, Sang We Kim, Thomas E. Boyd, Silvia Novello
Publikováno v:
Investigational New Drugs. 34:625-635
Introduction LY2603618 is a selective inhibitor of checkpoint kinase 1 (CHK1) protein kinase, a key regulator of the DNA damage checkpoint, and is predicted to enhance the effects of antimetabolites, such as pemetrexed. This phase II trial assessed t
Autor:
Naiyer A. Rizvi, David Smith, Jon M. Wigginton, David F. McDermott, Scott J. Antonia, David M. Jackman, Mario Sznol, Leena Gandhi, Richard D. Carvajal, Ashok Kumar Gupta, David R. Spigel, John D. Powderly, Rebecca S. Heist, Scott N. Gettinger, Mark E. Salvati, Lecia V. Sequist, Julie R. Brahmer, Matthew D. Hellmann, Mary Pinder-Schenck, Georgia Kollia, Christoph Matthias Ahlers, David P. Carbone, Suzanne L. Topalian, Philip D. Leming, Jeffrey A. Sosman, Drew M. Pardoll, Leora Horn, F. Stephen Hodi, Vindira Sankar
Publikováno v:
Journal of Clinical Oncology. 33:2004-2012
Purpose Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was active and generally well tolerated in patients with advanc
Autor:
Rob, Bevan, Charlie, Corke, Raymond, Raper, Mary, Pinder, Ross, Freebairn, Bala, Venkatesh, Dianne, Stephens, Gavin, Joynt, Peter, Morley, Rinaldo, Bellomo, Sarah, Yong, Stephen, Jacobe, Felicity, Hawker, Michael, Ashbolt, Stephen, Lam, Benoj, Varghese
Publikováno v:
Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. 19(2)
Autor:
Mary Pinder-Schenck, Angela Akar, Charles C. Williams, Alberto Chiappori, Jenny Kreahling, Julie A. Kish, Soner Altiok, Jhanelle E. Gray, Eric B. Haura, Richard Lush, Leticia Tetteh, Tawee Tanvetyanon, Xiuhua Zhao, Michael J. Schell, Gerold Bepler, Anthony Neuger
Publikováno v:
Clinical Cancer Research. 20:1644-1655
Purpose: Panobinostat, a histone deacetylase (HDAC) inhibitor, enhances antiproliferative activity in non–small cell lung cancer (NSCLC) cell lines when combined with erlotinib. We evaluated this combination in patients with advanced NSCLC and head